Veterinary Medicines

Biocan Novel DHPPi L4

Authorised
  • Canine distemper virus, strain CDV Bio 11/A, Live
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
  • Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
  • Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain MSLB 1089, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain MSLB 1090, Inactivated
  • Leptospira interrogans, serogroup Australis, serovar Bratislava, strain MSLB 1088, Inactivated
  • Leptospira kirschneri, serogroup Grippotyphosa, serovar Grippotyphosa, strain MSLB 1091, Inactivated
Download as PDF

Product identification

Medicine name:
Biocan Novel DHPPi L4
Biocan Novel DHPPi/L4, liofilizatas ir skiediklis injekcinei suspensijai ruošti šunims
Active substance:
  • Canine distemper virus, strain CDV Bio 11/A, Live
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
  • Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
  • Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain MSLB 1089, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain MSLB 1090, Inactivated
  • Leptospira interrogans, serogroup Australis, serovar Bratislava, strain MSLB 1088, Inactivated
  • Leptospira kirschneri, serogroup Grippotyphosa, serovar Grippotyphosa, strain MSLB 1091, Inactivated
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain CDV Bio 11/A, Live
    5.10
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
    5.30
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
  • Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
    6.60
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
  • Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
    5.10
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain MSLB 1089, Inactivated
    51.00
    Antibody microagglutination-lytic reaction
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain MSLB 1090, Inactivated
    51.00
    Antibody microagglutination-lytic reaction
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Australis, serovar Bratislava, strain MSLB 1088, Inactivated
    51.00
    Antibody microagglutination-lytic reaction
    /
    1.00
    Dose
  • Leptospira kirschneri, serogroup Grippotyphosa, serovar Grippotyphosa, strain MSLB 1091, Inactivated
    40.00
    Antibody microagglutination-lytic reaction
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Lithuania
Package description:
  • Glass Vial
  • Glass Vial
  • Glass Vial

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Bioveta a.s.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • State Food And Veterinary Service
Authorisation number:
  • LT/2/14/2250/001-003
Date of authorisation status change:
Reference member state:
  • Czechia
Procedure number:
  • CZ/V/0125/001
Concerned member states:
  • Bulgaria
  • Croatia
  • Cyprus
  • Estonia
  • Hungary
  • Latvia
  • Lithuania
  • Malta
  • Poland
  • Romania
  • Slovakia
  • Slovenia

Documents

RV2250.pdf

Lithuanian (PDF)
Published on: 30/05/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."